MarginsXMarginsX
Home › Markets › Health Care › CADL

Candel Therapeutics Inc. (CADL)

CADL trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$5.81
-6.29% on the day
Market cap
$455.8M
Small cap
Revenue · 2022
$125K
0.0% on 2021
Net income · 2022
-$18.8M
-15035.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2022-12-31, https://www.sec.gov/Archives/edgar/data/1841387/000095017024037637/0000950170-24-037637-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2022-12-31.

Profile

FieldValue
TickerCADL on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2021
SEC CIK0001841387
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2022

LineValue
Revenue$125K
Net income-$18.8M
Operating income-$34.7M
Net margin-15035.2%
Operating margin-27777.6%
Revenue growth0.0%
Cash$70.1M
Total assets$77.7M
P/E (computed)Net income was not positive
P/S (computed)3646.2×

Warning signs

Cash runway
35.4 months
$203.1M cash at September 30, 2026
Share count, 1 year
+42.9%
2025-11-05 to 2026-11-05 · +171.3% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
-$551K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$203.1M cash; operating cash flow -$17.2M a quarter.Report 2026-09-30
Shares outstanding78,445,937 (2026-11-05); 54,898,303 a year earlier; 28,919,810 three years earlier.Cover page 2026-11-05
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-11-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $3.0M, sold $3.6M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$21.9M-$23.1M$203.1M$1.1MNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed-$38.9M-$17.2M$201.6M$1.1MNeeds four quarters10-Q 2026-08-13
Q1 2026
2026-03-31
Not filed-$8.9M-$18.0M$194.8M$1.0MNeeds four quarters10-Q 2026-05-14
Q4 2025
2025-12-31
Not filed-$29.5M-$10.6M$119.7M$1.0MNeeds four quarters10-K 2026-03-12
Q3 2025
2025-09-30
Not filed-$11.3M-$10.2M$87.0M$5.2MNeeds four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
Not filed-$4.8M-$8.9M$100.7M$7.6MNeeds four quarters10-Q 2026-08-13
Q1 2025
2025-03-31
Not filed$7.4M-$8.6M$92.2M$10.1MNeeds four quarters10-Q 2026-05-14
Q4 2024
2024-12-31
Not filed-$14.1M-$5.8M$102.7M$11.6MNeeds four quarters10-K 2026-03-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-11-12
Latest annual report10-K2026-03-12
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 423 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-29.1%
1 month-33.1%
3 months-47.5%
Year to date+9.7%
1 year+34.5%
From 52-week high-54.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
FENCFennec Pharmaceuticals Inc.$12.76+9.81%$450.5M
RGNXREGENXBIO Inc.$7.32-4.19%$484.0M
TVGNTevogen Inc.$6.22+3.67%$422.2M
TECXTectonic Therapeutic Inc.$20.98-0.76%$418.5M
IRLAIRulya Therapeutics Inc.$37.36-6.13%$405.0M
SLBTSL Science Holding Limited$0.7195-3.42%$403.5M
ETRAElectra Therapeutics Inc.$8.31-6.00%$522.4M
ENTXEntera Bio Ltd.$3.02-2.89%$525.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier